NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...
U.S. physicians indicate an almost 50-50 split when asked whether trackable pills will improve patient outcomes, according to a recent survey by SERMO, a global social network for physicians. The ...
NEW YORK, July 17 (Reuters) - Bristol-Myers Squibb Co. and Japan's Otsuka Pharmaceutical Co. said on Tuesday that U.S. health regulators have granted a priority review for their schizophrenia drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback